Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

38 results about "Metal poisoning" patented technology

Acute or chronic disease due to exposure to a metal or its salts.

Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.
Owner:HEALTHPARTNERS RESEACH FOUND

Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning

ActiveUS20070092500A1Preventing and minimizing and treating neurologic complicationAvoid side effectsOrganic active ingredientsBiocideAntioxidantNose
Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
Owner:HEALTHPARTNERS RESEACH FOUND

Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia

Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and / or post stroke.
Owner:HEALTHPARTNERS RESEACH FOUND

Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity

ActiveUS7776312B2Avoid side effectsStimulate and stabilize HIF-1αBiocideOrganic active ingredientsNervous systemNose
Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and / or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
Owner:HEALTHPARTNERS RESEACH FOUND

Novel cerium oxide denitration catalyst and preparation method thereof

The invention discloses a novel cerium oxide denitration catalyst. The novel cerium oxide denitration catalyst has the expression formula of CeNaOx, wherein the molar ratio of Ce to Na is (90-98):(10-2), and x is balanced and determined by positive and negative valence electrons in each atom. The preparation method of the catalyst comprises the following steps of: 1, dissolving cerous sulfate, sodium phosphate and cerium sulfate in water at normal temperature, and stirring to form a transparent solution; 2, transferring the prepared solution into a hydrothermal reaction kettle, and adding deionized water; 3, sealing the hydrothermal reaction kettle and transferring the hydrothermal reaction kettle to an oven for heating and reacting, reducing the temperature, performing centrifugal separation, and cleaning until no sulfate radical is detected by using deionized water; and 4, drying and roasting the centrifuged precipitate, thereby obtaining the catalyst. The metallic oxide catalyst is in the range of 200-500 DEG C, and the purification efficiency of nitric oxide is 71-100 percent; and the composite oxide catalyst has high high-altitude-resistant speed and good alkali-resistant metal poisoning performance, the efficiency is greatly improved, and the operating cost can be obviously reduced.
Owner:江苏中创清源科技有限公司

Novel cerium oxide denitration catalyst and preparation method thereof

ActiveCN103007919AGood resistance to high airspeedGood resistance to alkali metal poisoningDispersed particle separationMetal/metal-oxides/metal-hydroxide catalystsSulfate radicalsValence electron
The invention discloses a novel cerium oxide denitration catalyst. The novel cerium oxide denitration catalyst has the expression formula of CeNaOx, wherein the molar ratio of Ce to Na is (90-98):(10-2), and x is balanced and determined by positive and negative valence electrons in each atom. The preparation method of the catalyst comprises the following steps of: 1, dissolving cerous sulfate, sodium phosphate and cerium sulfate in water at normal temperature, and stirring to form a transparent solution; 2, transferring the prepared solution into a hydrothermal reaction kettle, and adding deionized water; 3, sealing the hydrothermal reaction kettle and transferring the hydrothermal reaction kettle to an oven for heating and reacting, reducing the temperature, performing centrifugal separation, and cleaning until no sulfate radical is detected by using deionized water; and 4, drying and roasting the centrifuged precipitate, thereby obtaining the catalyst. The metallic oxide catalyst is in the range of 200-500 DEG C, and the purification efficiency of nitric oxide is 71-100 percent; and the composite oxide catalyst has high high-altitude-resistant speed and good alkali-resistant metal poisoning performance, the efficiency is greatly improved, and the operating cost can be obviously reduced.
Owner:江苏中创清源科技有限公司

Metal-poisoning in-vivo-extract checking device

The invention relates to a metal-poisoning in-vivo-extract checking device, and belongs to the technical field of medical apparatuses and instruments. The metal-poisoning in-vivo-extract checking device comprises a base disc, a current-variator support fixing disc is arranged on the upper side of the base disc, a current-variator support is arranged on the upper side of the current-variator support fixing disc, a current variator is arranged on the upper side of the current-variator support, an inner sliding rod and a resistor are arranged inside the current variator, a sliding-rod slider is arranged on the inner sliding rod, a sliding-information receiver is arranged on the front side of the sliding-rod slider, an electric-shocking conical head support is arranged on the right side of the sliding-rod slider, an electric-shocking conical head is arranged on the right side of the electric-shocking conical head support, and a stretching line fixer is arranged on the electric-shocking conical head support. The metal-poisoning in-vivo-extract checking device is complete in function and convenient to use, and when the metal element content of metal-poisoning patients is checked, the device is safe and efficient, time and labor are saved, and workloads of medical workers are greatly reduced.
Owner:赵红梅
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products